Table 3.
Efficacy Endpoints in the OLE Study
| MNTX PRN (n=147)a | |
|---|---|
| Number of BMs within 24 hours of dosing per patient per week, mean (SD) | |
| Range per week (minimum, maximum) | 2.2 (1.6) to 3.1 (3.0) |
| Overall (10 weeks) | 13.9 (15.9) |
| Number of days with BMs within 24 hours of dosing per patient per week, mean (SD), days | |
| Range per week (minimum, maximum) | 1.7 (1.1) to 2.0 (1.6) |
| Overall (10 weeks) | 9.6 (9.3) |
| Percentage of injections resulting in BM within 4 hours, mean (SD) | 54.9 (33.4) |
a
Two patients in the MNTX 12 mg group did not have diary data and were not included in the efficacy analyses.
BM, bowel movement; MNTX, methylnaltrexone; OLE, open-label extension; PRN, as needed; SD, standard deviation.